Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

NCT03040973 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors Which Are cMET-dependent

Interventions

DRUG: Capmatinib
DRUG: Nazartinib
DRUG: Gefitinib
DRUG: Osimertinib

Sponsor

Novartis Pharmaceuticals